Literature DB >> 11971028

A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape.

Heinz Wiendl1, Meike Mitsdoerffer, Valeska Hofmeister, Jörg Wischhusen, Antje Bornemann, Richard Meyermann, Elisabeth H Weiss, Arthur Melms, Michael Weller.   

Abstract

HLA-G is a nonclassical MHC molecule with highly limited tissue distribution that has been attributed chiefly immune regulatory functions. Glioblastoma is paradigmatic for the capability of human cancers to paralyze the immune system. To delineate the potential role of HLA-G in glioblastoma immunobiology, expression patterns and functional relevance of this MHC class Ib molecule were investigated in glioma cells and brain tissues. HLA-G mRNA expression was detected in six of 12 glioma cell lines in the absence of IFN-gamma and in 10 of 12 cell lines in the presence of IFN-gamma. HLA-G protein was detected in four of 12 cell lines in the absence of IFN-gamma and in eight of 12 cell lines in the presence of IFN-gamma. Immunohistochemical analysis of human brain tumors revealed expression of HLA-G in four of five tissue samples. Functional studies on the role of HLA-G in glioma cells were conducted with alloreactive PBMCs, NK cells, and T cell subpopulations. Expression of membrane-bound HLA-G1 and soluble HLA-G5 inhibited alloreactive and Ag-specific immune responses. Gene transfer of HLA-G1 or HLA-G5 into HLA-G-negative glioma cells (U87MG) rendered cells highly resistant to direct alloreactive lysis, inhibited the alloproliferative response, and prevented efficient priming of cytotoxic T cells. The inhibitory effects of HLA-G were directed against CD8 and CD4 T cells, but appeared to be NK cell independent. Interestingly, few HLA-G-positive cells within a population of HLA-G-negative tumor cells exerted significant immune inhibitory effects. We conclude that the aberrant expression of HLA-G may contribute to immune escape in human glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971028     DOI: 10.4049/jimmunol.168.9.4772

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  89 in total

1.  Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Authors:  Nichole L Bryant; G Yancey Gillespie; Richard D Lopez; James M Markert; Gretchen A Cloud; Catherine P Langford; Hilal Arnouk; Yun Su; Hilary L Haines; Catalina Suarez-Cuervo; Lawrence S Lamb
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

Review 2.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

3.  Isoforms of the nonclassical class I MHC antigen H2-Q5 are enriched in brain and encode Qdm peptide.

Authors:  Nora E Renthal; Paula A Guidry; Sharmila Shanmuganad; William Renthal; Iwona Stroynowski
Journal:  Immunogenetics       Date:  2010-10-22       Impact factor: 2.846

Review 4.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

Review 5.  Emerging topics and new perspectives on HLA-G.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Marina Stignani; Fabio Morandi; Gwenaëlle Sana; Rafael Gonzalez; Vito Pistoia; Olavio Roberto Baricordi; Etienne Sokal; Josè Peña
Journal:  Cell Mol Life Sci       Date:  2010-11-16       Impact factor: 9.261

Review 6.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 7.  Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Authors:  William Tomaszewski; Luis Sanchez-Perez; Thomas F Gajewski; John H Sampson
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

8.  Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.

Authors:  Neil T Hoa; Lisheng Ge; Kate L Erickson; Carol A Kruse; Andrew N Cornforth; Yurii Kuznetsov; Alex McPherson; Filippo Martini; Martin R Jadus
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

9.  A critical role of non-classical MHC in tumor immune evasion in the amphibian Xenopus model.

Authors:  Nikesha Haynes-Gilmore; Maureen Banach; Eva-Stina Edholm; Edith Lord; Jacques Robert
Journal:  Carcinogenesis       Date:  2014-04-28       Impact factor: 4.944

Review 10.  Soluble HLA-G: Are they clinically relevant?

Authors:  Vito Pistoia; Fabio Morandi; Xinhui Wang; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2007-07-31       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.